Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease

While the CNS has long been viewed as an immune-privileged environment, a paradigm shift in neuro-immunology has elevated the role of systemic immunotherapy for the treatment of metastatic disease. Increasing knowledge regarding the presence of a CNS lymphatic system and the physical and biochemical alteration of the blood brain barrier (BBB) by the tumor microenvironment suggests immune cell trafficking in and out of the CNS is possible. Emerging clinical data suggest immune checkpoint inhibitors (ICIs) can stimulate T cells peripherally to in turn have anti-tumor effects in the CNS. For example, anti-programmed cell death-1 (PD-1) monotherapy with pembrolizumab has shown intracranial response rates of 20–30% in patients with melanoma or non-small cell lung cancer (NSCLC) brain metastases. The combination of nivolumab and ipilimumab [anti-PD-1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)] showed an intracranial response rate of 55% in patients with melanoma brain metastases. More data are needed to confirm these response rates and to determine mechanisms of efficacy and resistance. While local therapies such as stereotactic radiosurgery (SRS), whole-brain radiation therapy (WBRT), and surgery remain current mainstays, ICIS offer potential decreased neurotoxicity. This review summarizes the biological rationale for systemic immunotherapy to treat CNS metastatic disease, existing clinical data on ICIs in this setting and ongoing clinical trials exploring areas of unmet need.

[1]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[2]  Susan M. Chang,et al.  Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. , 2018, The Lancet. Oncology.

[3]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[4]  M. Atkins,et al.  Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. , 2017 .

[5]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[6]  S. Kesari,et al.  Mutational complexity increases in lung adenocarcinoma (LADC) with the development of brain metastasis (BM). , 2018 .

[7]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[8]  F. Hodi,et al.  Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[10]  R. Camidge,et al.  A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Edward S. Kim,et al.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Neefjes,et al.  Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. , 2008, Oncology.

[13]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[14]  P. Ascierto,et al.  Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases , 2014, Journal of Neuro-Oncology.

[15]  S. Swetter,et al.  A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.

[16]  P. Ascierto,et al.  Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. , 2012, The Lancet. Oncology.

[17]  Timothy J Keyes,et al.  Structural and functional features of central nervous system lymphatics , 2015, Nature.

[18]  C. Porta,et al.  Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme , 2018, BJU international.

[19]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[20]  B. Young,et al.  Demographics of brain metastasis. , 1996, Neurosurgery clinics of North America.

[21]  T. Wise-Draper,et al.  Brain metastases treated with immune checkpoint inhibitors: A single center experience. , 2018 .

[22]  M. Zucchetti,et al.  Do anticancer agents reach the tumor target in the human brain? , 2004, Cancer Chemotherapy and Pharmacology.

[23]  R. Herbst,et al.  Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. , 2018 .

[24]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[25]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[26]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[27]  V. Jindal,et al.  Expected Paradigm Shift in Brain Metastases Therapy—Immune Checkpoint Inhibitors , 2018, Molecular Neurobiology.

[28]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[29]  Jennie W. Taylor,et al.  Clinical trial endpoints for patients with gliomas. , 2017, Neuro-oncology practice.

[30]  Brady T. West,et al.  Ipilimumab and radiation therapy for melanoma brain metastases , 2013, Cancer medicine.

[31]  Jie Zhou,et al.  Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer. , 2018, Biochemical and biophysical research communications.

[32]  A. Delmonte,et al.  Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy , 2016 .

[33]  G. Ricken,et al.  1324PTUMOR-INFILTRATING LYMPHOCYTES (TILS) AND PD-L1 EXPRESSION IN NON- SMALL CELL LUNG CANCER BRAIN METASTASES (BM) AND MATCHED PRIMARY TUMORS (PT). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[35]  P. Knight,et al.  Epidemiology and Pathophysiology , 1990 .

[36]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[37]  C. Drake,et al.  Systemic depletion of lymphocytes following focal radiation to the brain in a murine model , 2018, Oncoimmunology.

[38]  P. Steeg,et al.  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.

[39]  H. Nechushtan,et al.  Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. , 2016, Lung cancer.

[40]  J. Posner,et al.  Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.

[41]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[42]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[43]  D. Planchard,et al.  1323PBaseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients , 2017 .

[44]  G. Collins.  The next generation. , 2006, Scientific American.

[45]  A. Brodbelt,et al.  T-Cell Densities in Brain Metastases Are Associated with Patient Survival Times and Diffusion Tensor MRI Changes. , 2018, Cancer research.

[46]  M. Ahluwalia,et al.  Efficacy of immune checkpoint inhibitors in patients with brain metastasis from NSCLC, RCC, and melanoma. , 2018 .

[47]  P. Ascierto,et al.  Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  L. Lampson.  Monoclonal antibodies in neuro-oncology , 2011, mAbs.

[49]  D. Gomez,et al.  Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? , 2014, Cancer Immunology Research.

[50]  P. Ascierto,et al.  A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. , 2015 .

[51]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[52]  H. Heinzl,et al.  Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases , 2016, Oncoimmunology.

[53]  J. Knisely,et al.  Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. , 2012, Journal of neurosurgery.

[54]  H. Honda,et al.  Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation , 2018, AntiCancer Research.

[55]  I. Kaplan,et al.  Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review , 2015, Journal of Immunotherapy for Cancer.

[56]  J. Weber.  Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. , 2010, Seminars in oncology.

[57]  Eudocia Q Lee,et al.  Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. , 2018, The Lancet. Oncology.

[58]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[59]  S. Demaria,et al.  Radiation as an immunological adjuvant: current evidence on dose and fractionation , 2012, Front. Oncol..

[60]  A. Giobbie-Hurder,et al.  Phase II study of pembrolizumab in leptomeningeal carcinomatosis. , 2018 .